Clinical Trials Logo

Neurotrophic Keratitis clinical trials

View clinical trials related to Neurotrophic Keratitis.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05566717 Recruiting - Clinical trials for Diabetic Retinopathy

An Investigator-Initiated Study to Assess the Association of Diabetic Retinopathy Severity Scale (DRSS) With Level of Decreased Corneal Sensitivity

Assess
Start date: July 1, 2022
Phase:
Study type: Observational

Evaluate the association between level of decreased corneal sensitivity and diabetic retinopathy severity scale

NCT ID: NCT05552261 Recruiting - Clinical trials for Neurotrophic Keratitis

DEFENDO Long Term Follow-up Study in Stage 1 NK Patients

DEFENDO
Start date: December 20, 2022
Phase:
Study type: Observational

The primary objectives are to evaluate the long-term safety and efficacy of OXERVATEâ„¢ 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution in Stage 1 Neurotrophic Keratitis (NK) patients who enrolled in the DEFENDO Study.

NCT ID: NCT04909450 Recruiting - Clinical trials for Neurotrophic Keratitis

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects

Start date: August 24, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This study will enroll subjects with stage 2 or 3 neurotrophic keratitis. Subjects will be randomized in a 1:1 ratio to the CSB-001 investigational treatment arm or vehicle control arm. All subjects will dose with the randomized treatment four times daily for 8 weeks (controlled treatment phase). During the controlled treatment phase, subjects will return to the clinic weekly from Day 0 to Week 8, and again at Week 10. Subjects randomized to the vehicle arm who are not healed will have the opportunity to participate in an open-label uncontrolled treatment phase.

NCT ID: NCT04627571 Recruiting - Clinical trials for Neurotrophic Keratitis

Corneal Nerves After Treatment With Cenegermin

Start date: May 23, 2022
Phase:
Study type: Observational

Neurotrophic keratopathy (NK) is a condition in which patients have fewer or complete absence of nerves in the cornea, characterized by the reduced or absent corneal sensation. The lack of nerves in the cornea also result in damages of the cornea and in severe situation the loss of the eye. Cenegermin (trade name Oxervate) is a nerve growth factor eye drops designed to treat NK, and currently, it is the only FDA-approved medication for this purpose. Even though cenegermin is effective in the majority of patients, there is a lack of understanding of how cenegermin works in the eye. In this study, investigators aim to determine the structural and functional effects of cenegermin on the cornea, using non-invasive technologies including in vivo confocal microscopy on study participants with NK over the course of a year.

NCT ID: NCT04573647 Recruiting - Clinical trials for Neurotrophic Keratitis

OCT Evaluation of Neurotrophic Ulcer Following Treatment With Oxervate

Start date: October 1, 2020
Phase:
Study type: Observational

Neurotrophic keratitis (NK) is a condition where the cornea, or clear outer covering of the eye, has reduced sensation due to a variety of reasons. In more advanced cases of NK, the cornea can develop an area of thinning called an ulcer. The purpose of this research is to find out if Oxervate (cenegermin-bkbj 0.002%) an FDA-approved treatment for neurotrophic corneal ulcers leads to an increase in thickness of the corneal stroma (middle layer of the cornea) during and after treatment of a neurotrophic ulcer. Corneal thickness will be measured using optical coherence tomography (OCT), a non-contact imaging device used routinely in ophthalmology examinations. Corneal sensation will also be measured during and after treatment with a device called a Cochet-Bonnet esthesiometer to see if the treatment increases corneal sensation.